Published in J Viral Hepat on January 01, 2006
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect (2013) 2.09
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 1.60
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) (2014) 1.53
Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS (2013) 1.51
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother (2009) 1.50
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol (2007) 1.44
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis (2013) 1.26
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25
Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis (2012) 1.24
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett (2010) 1.22
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Hepatitis C infection in HIV-1 natural viral suppressors. AIDS (2010) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One (2012) 1.09
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics (2009) 1.07
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon (2012) 1.05
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One (2014) 0.99
Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis (2011) 0.99
Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.98
Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLoS One (2013) 0.98
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis (2012) 0.95
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open (2013) 0.95
The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion (2010) 0.94
Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. Viruses (2009) 0.94
Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis (2010) 0.92
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol (2007) 0.91
Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int (2011) 0.90
Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis (2012) 0.90
A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion (2010) 0.90
The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon (2014) 0.90
Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care. Can J Gastroenterol Hepatol (2015) 0.90
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J (2014) 0.89
Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One (2013) 0.88
Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. Clin Infect Dis (2015) 0.88
Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol (2014) 0.87
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One (2015) 0.87
Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol (2015) 0.86
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis (2015) 0.85
Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? J Med Virol (2012) 0.85
Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. Hepat Mon (2014) 0.85
Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. J Viral Hepat (2013) 0.85
Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B (2014) 0.85
Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health (2014) 0.84
MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses (2012) 0.84
Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol (2014) 0.84
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One (2008) 0.84
NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol (2012) 0.84
Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med (2012) 0.84
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One (2013) 0.83
Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J (2011) 0.83
Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. J Prev Med Hyg (2013) 0.83
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepat Mon (2014) 0.83
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (2016) 0.82
Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence (2015) 0.82
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol (2014) 0.82
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat (2015) 0.82
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. PLoS One (2011) 0.82
Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One (2012) 0.82
Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis? World J Gastroenterol (2013) 0.81
Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis. CMAJ Open (2014) 0.81
Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol (2013) 0.81
Acute hepatitis C in an HIV-infected patient: a case report and review of literature. J Gen Intern Med (2012) 0.81
HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS One (2014) 0.81
Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. Clin Infect Dis (2013) 0.81
Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients. World J Gastroenterol (2015) 0.81
New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat (2016) 0.81
The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med (2015) 0.81
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. PLoS One (2013) 0.81
IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics (2013) 0.80
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet (1997) 2.97
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Clinical spectrum of HIV/AIDS in the Asia-Pacific region. AIDS (1998) 2.19
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16
Trends in infectious disease mortality in Australia, 1979-1994. Med J Aust (1998) 2.02
Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ (1997) 1.92
Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust (2000) 1.92
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78
Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer (1988) 1.74
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect (2006) 1.59
Perinatal exposure to HIV in Australia, 1982-1994. Med J Aust (1997) 1.54
Survival analyses of randomized clinical trials adjusted for patients who switch treatments. Stat Med (1996) 1.54
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52
Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol (1997) 1.52
Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust (2000) 1.50
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46
Oral contraceptives and breast cancer: a national study. Br Med J (Clin Res Ed) (1986) 1.44
Detection of HCV RNA in semen. Lancet (2000) 1.41
Sexually transmissible diseases surveillance in Australia: towards a coordinated national system. Commun Dis Intell (1998) 1.40
Use of interventions for reducing mother-to-child transmission of HIV in Australia. Med J Aust (2001) 1.40
Premature mortality in Australia 1983-1992, the first decade of the AIDS epidemic. Med J Aust (1995) 1.40
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
Reporting of occupational exposures to blood-borne pathogens in Australian teaching hospitals. Med J Aust (1995) 1.38
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med (2007) 1.36
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee. Am J Public Health (1994) 1.32
Circumcision and male-to-male sexual transmission of HIV. AIDS (2001) 1.30
Kaposi's sarcoma and protection from AIDS dementia complex. AIDS (1998) 1.30
HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. Med J Aust (1997) 1.26
HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS (1998) 1.24
Predictors of recent HIV testing in homosexual men in Australia. HIV Med (2002) 1.23
The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend (2005) 1.23
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat (2007) 1.23
The benefits and risks of mammographic screening for breast cancer. Epidemiol Rev (1992) 1.23
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
HIV surveillance in hard-to-reach populations. AIDS (2001) 1.22
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
Self-report is a valid measure of circumcision status in homosexual men. Sex Transm Infect (2008) 1.18
Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer (1987) 1.15
HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans R Soc Trop Med Hyg (1999) 1.09
Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.08
Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. HIV Med (2009) 1.08
Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat (2015) 1.05
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect (2006) 1.04
Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat (2011) 1.02
HIV prevalence at reception into Australian prisons, 1991-1997. Med J Aust (1999) 1.01
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01
Secondary malignancies following cancer chemotherapy. Acta Oncol (1994) 0.99
Age-specific HIV incidence among homosexually active men in Australia. Med J Aust (1996) 0.98
A case-control study of diet and breast cancer in Argentina. Int J Cancer (1989) 0.98
Fertility and reproductive choice in women with HIV-1 infection. AIDS (1997) 0.95
Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis (1997) 0.94
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res Hum Retroviruses (1998) 0.94
The usage and costs of health services for HIV infection in Australia. AIDS (1995) 0.94
Epidemiology of HIV and AIDS in the Asia-Pacific region. Med J Aust (1996) 0.93
Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat (2010) 0.92
Aplastic anemia, leukemia and other cancer mortality in a cohort of shoe workers exposed to benzene. Scand J Work Environ Health (1989) 0.92
Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med (2004) 0.92
HIV infection in recipients of blood products from donors with known duration of infection. Lancet (1994) 0.92
Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med (2007) 0.91
Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings. HIV Med (2010) 0.91
Prevalence of hepatitis C virus antibodies in Sydney blood donors. Med J Aust (1992) 0.90
An outbreak of a penicillin-sensitive strain of gonorrhoea in Sydney men. Genitourin Med (1994) 0.90
Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. J Viral Hepat (2011) 0.90
Public health challenges in hepatitis C virus infection. J Gastroenterol Hepatol (2000) 0.89
Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sang (2001) 0.88
Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat (2003) 0.87
Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat (2010) 0.87
Can data from HIV voluntary counselling and testing be used to assess the impact of public health interventions? A literature review. Int J STD AIDS (2009) 0.86
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS (1996) 0.86
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS (2000) 0.86
Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med (2002) 0.86